A weekly dose of semaglutide at three times the currently approved level was associated with significant weight loss compared to both the currently approved dose and placebo, according to the results of a pair of large, international studies involving adults with obesity, with and without diabetes. “Many patients [with obesity] have done well on semaglutide at 2.4-mg doses, […]
Anne L. Peters, MD September 05, 2025 This transcript has been edited for clarity. Today, I’m going to discuss a study that was just published in Diabetes Care by a group of researchers from Israel. Basically, they looked at whether a very slow uptitration of semaglutide was beneficial compared to the on-label, more rapid uptitration of semaglutide. Now, first off, I
The Click Method: Slower Uptitration for Semaglutide Read More »
JAMA Network Open Peer-Reviewed Publication JAMA NETWORK About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders, although the overall risk was low. These findings highlight the need
Patients treated with tirzepatide have a significantly increased likelihood of attaining combined key therapeutic targets in the control of type 2 diabetes (T2D) compared with semaglutide, a post hoc analysis of the phase 3 SURPASS-2 trial showed. “In this post hoc analysis, we showed that tirzepatide was superior to semaglutide in achieving standard and intensive
Tirzepatide Outperforms Semaglutide on Combined T2D Goals – Read More »
by Oregon Health & Science University edited by Robert Egan Credit: Unsplash/CC0 Public Domain A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with type 1 diabetes who use automated insulin delivery systems. The results are published today in the
TOPLINE: At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic optic neuropathy (NAION), according to a case series. Researchers hypothesize that rapid correction of hyperglycemia induced by these drugs may be associated with eye disorders. METHODOLOGY: Researchers reported on
Eye Complications Found With Use of Semaglutide, Tirzepatide Read More »
TOPLINE: An analysis of data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database revealed differences in patterns of ocular events associated with oral and injectable formulations of semaglutide, with injectable formulations linked to a higher frequency of retinal complications. METHODOLOGY: The FDA has approved semaglutide as both a subcutaneous injection for
Oral, Injected Semaglutide May Pose Distinct Eye Risks Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866